Your session is about to expire
← Back to Search
Combination Chemotherapy for Acute Myeloid Leukemia
Study Summary
This trial tests how well 4 different drugs work to treat leukemia, myelodysplastic syndrome, or blastic phase chronic myeloid leukemia.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2011 Phase 3 trial • 867 Patients • NCT00641537Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have been diagnosed with AML, acute biphenotypic leukemia, high risk MDS, or CML in myeloid blast phase.I can take care of myself but might not be able to do heavy physical work.I understand the study's requirements and have signed the consent form.I am using contraception or agree to use it during the study.I have leukemia and haven't had curative therapy; I may receive venetoclax.I do not have any uncontrolled illnesses.I have relapsed or refractory AML, acute biphenotypic leukemia, or CML in myeloid blast phase.
- Group 1: Treatment (cladribine, cytarabine, idarubicin)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has Cladribine been granted endorsement by the Food and Drug Administration?
"Given the Phase 2 status of Cladribine, our staff at Power assigned it a score of 2 on the safety scale due to some data confirming its security but no evidence demonstrating its efficacy."
Are there any vacancies for participation in this experiment?
"The clinicaltrials.gov listing confirms that this study is seeking participant enrolment at the time of writing; it was initially posted on May 19th 2014, with its most recent update occurring February 15th 2022."
Does my profile qualify me to participate in this examination?
"This clinical trial is enlisting 458 subjects aged 18 to 65 who have been diagnosed with leukemia, myelogenous chronic BCR-ABL positive. For successful entry into the study, patients must meet a range of stipulations: A diagnosis of AML, acute biphenotypic leukemia or high risk MDS (>= 10% blasts or IPSS >= intermediate-2); no prior potentially curative therapy for leukaemia (aside from hydroxyurea, hematopoietic growth factors and other medications), ECOG performance status =< 2; and those eligible for venetoclax are assigned to frontline cohort"
To what conditions is Cladribine typically prescribed?
"Cladribine is an oft-used drug to treat meningeal leukemia and other severe conditions, e.g. acute myeloid leukemia, pediatric blast phase chronic myelocytic leukemia, and acute myelocytic leukemia."
Does the research permit participation from octogenarians?
"This research requires that participants are of legal age and under 65 years old."
Are there any prior experiments that have been performed with Cladribine as a part of the treatment?
"Presently, there are 454 trials ongoing for Cladribine, with 92 of those being in Phase 3. Edmonton, Alberta is the primary location running these tests; however there are 17,566 sites executing studies on this medication."
What is the aggregate amount of participants involved in this experiment?
"Indeed, clinicaltrials.gov affirms that this research is actively recruiting individuals as of now. This initiative was inaugurated on May 19th 2014 and its parameters were most recently adjusted on February 15th 2022. 458 participants are sought from a single medical facility."
Share this study with friends
Copy Link
Messenger